JW PHARMACEUTICAL
Financials
Valuation Metrics
JW PHARMACEUTICAL's Market Cap is ₩5804B. At end of 2025 it was ₩6496B. Ranked #401 of 2,410 in KR market (top 17%), #264 of 779 on KOSPI (top 34%), #45 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 19%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 580.38B KRW | KR#401/2,410 Sec#45/231 |
| Revenue | 820.86B KRW | KR#454/2,410 Sec#20/231 |
| Net Income | 101.28B KRW | KR#249/2,410 Sec#13/231 |
| Total Assets | 605.27B KRW | KR#676/2,410 Sec#37/231 |
| Net Assets | 369.37B KRW | KR#631/2,410 Sec#40/231 |
| Employees | 1,107 | KR#238/2,410 Sec#14/231 |
| Value | ||
| P/E | 5.73x | KR#498/2,410 Sec#21/231 |
| P/B | 1.57x | KR#1,854/2,410 Sec#133/231 |
| PEG | 0.06x | KR#349/2,410 Sec#19/231 |
| P/S | 0.71x | KR#1,216/2,410 Sec#64/231 |
| EV/EBITDA | 5.01x | KR#275/2,410 Sec#5/231 |
| FCF Yield | 14.58% | KR#501/2,410 Sec#15/231 |
| Profitability | ||
| ROE | 27.42% | KR#76/2,410 Sec#6/231 |
| ROA | 16.73% | KR#81/2,410 Sec#7/231 |
| Op. Margin | 13.94% | KR#332/2,410 Sec#31/231 |
| Revenue Growth | 10.50% | KR#872/2,410 Sec#84/231 |
| Earnings Growth | 94.60% | KR#409/2,410 Sec#29/231 |
| Financial Health | ||
| Debt Ratio | 63.87% | KR#1,140/2,410 Sec#134/231 |
| Total Debt | 32.10B KRW | KR#1,191/2,410 Sec#89/231 |
| FCF | 84.62B KRW | KR#219/2,410 Sec#13/231 |
| Cash | 39.23B KRW | KR#864/2,410 Sec#55/231 |
| Current Ratio | 1.56x | KR#1,143/2,410 Sec#124/231 |
| Net Debt/EBITDA | -0.06x | KR#589/2,410 Sec#36/231 |
| Dividend | ||
| Div. Yield | 2.84% | KR#745/2,410 Sec#37/231 |
| Div. Growth | 44.44% | KR#272/2,410 Sec#12/231 |
| Performance | ||
| 1Y Return | -2.55% | KR#573/2,410 Sec#33/231 |
| 1M Return | -14.39% | KR#1,505/2,410 Sec#153/231 |
| From 52W High | -41.66% | KR#775/2,410 Sec#55/231 |
| 1Y MDD | -43.66% | KR#699/2,410 Sec#50/231 |
| Trading | ||
| Volume | 12,997 shares | KR#1,506/2,410 Sec#153/231 |
| Trading Value | 298.3M KRW | KR#832/2,410 Sec#86/231 |
| Foreign Own. | 7.34% | KR#607/2,410 Sec#51/231 |
| Per Share | ||
| EPS | 3,996 KRW | KR#264/2,410 Sec#16/231 |
| BPS | 14,574 KRW | KR#721/2,410 Sec#47/231 |
Company Info
The company began as Joseon Choongwae Pharmaceutical Laboratory in 1945, incorporated in 1953, and expanded its business in 2019 by acquiring Vietnamese Euvipharm after listing in 1976. It holds products such as Livalo, Hemlibra, Trupass, Actemra, and the 3rd-generation 3-chamber nutritional infusion Winuf. The company leads the market with its combined novel drug of pitavastatin and ezetimibe. Utilizing the JWAVE platform, it applies AI models across the entire new drug development cycle to reduce time and cost. JW Pharmaceutical is headquartered in Gwacheon, Gyeonggi-do.